Sung‐Bae Kim
Impact in
- Oncology top 0.05%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Cancer Research top 0.2%
- Breast Cancer Treatment Studies
Papers in
- Oncology 109
- HER2/EGFR in Cancer Research 51
- Cancer Treatment and Pharmacology 25
-
- Head and Neck Cancer Studies 30
- Co-authors
- Javier Cortés (12 shared papers)Graham A. Ross (3 shared papers)Emma Clark (3 shared papers)Mark C. Benyunes (3 shared papers)Sandra M. Swain (3 shared papers)Jean-Marc Ferrero (4 shared papers)Jungsil Ro (14 shared papers)Seock‐Ah Im (27 shared papers)
- Journals
- Cancer Research and Treatment (23 papers)The Lancet Oncology (18 papers)Breast Cancer Research and Treatment (16 papers)Journal of Clinical Oncology (14 papers)European Journal of Cancer (14 papers)
- Partner nations
- South KoreaUnited StatesSpain
In The Last Decade
Sung‐Bae Kim
362 papers receiving 31.2k citations
Sung‐Bae Kim's Hit Papers
Peers
Comparison fields: 5 of 162
- Oncology 15.9k
- Cancer Research 4.8k
- Otorhinolaryngology 1.1k
- Pulmonary and Respiratory Medicine 7.4k
- Radiology, Nuclear Medicine and Imaging 4.4k
Countries citing papers authored by Sung‐Bae Kim
This map shows the geographic impact of Sung‐Bae Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sung‐Bae Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sung‐Bae Kim more than expected).
Fields of papers citing papers by Sung‐Bae Kim
This network shows the impact of papers produced by Sung‐Bae Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sung‐Bae Kim. The network helps show where Sung‐Bae Kim may publish in the future.
Co-authors
The 25 scholars most cited alongside Sung‐Bae Kim, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 385 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer Hit paper breakdown → | 2011 | 2024 |
| 2 | Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer Hit paper breakdown → | 2022 | 1875 |
| 3 | Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer Hit paper breakdown → | 2015 | 1669 |
| 4 | Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer Hit paper breakdown → | 2015 | 1594 |
| 5 | Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer Hit paper breakdown → | 2019 | 1575 |
| 6 | Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy Hit paper breakdown → | 2017 | 1379 |
| 7 | Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study Hit paper breakdown → | 2018 | 1366 |
| 8 | Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study Hit paper breakdown → | 2021 | 1116 |
| 9 | Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial Hit paper breakdown → | 2019 | 894 |
| 10 | Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer Hit paper breakdown → | 2020 | 832 |
| 11 | Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study Hit paper breakdown → | 2013 | 808 |
| 12 | Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study Hit paper breakdown → | 2020 | 668 |
| 13 | Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2014 | 588 |
| 14 | Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2023 | 521 |
| 15 | Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial Hit paper breakdown → | 2020 | 482 |
| 16 | Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial Hit paper breakdown → | 2022 | 472 |
| 17 | 2007 | 462 | |
| 18 | Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2017 | 461 |
| 19 | 2017 | 436 | |
| 20 | 2017 | 414 |
About Sung‐Bae Kim
Sung‐Bae Kim is a scholar working on Oncology, Otorhinolaryngology, Cancer Research, Pulmonary and Respiratory Medicine and Surgery, having authored 385 papers that have together received 31.9k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (51 papers), Breast Cancer Treatment Studies (35 papers), Esophageal Cancer Research and Treatment (31 papers), Head and Neck Cancer Studies (30 papers), Cancer Treatment and Pharmacology (25 papers), Advanced Breast Cancer Therapies (22 papers), Structural Behavior of Reinforced Concrete (21 papers) and Esophageal and GI Pathology (17 papers). The work is most often cited by research in Oncology (15.9k citations), Cancer Research (4.8k citations), Otorhinolaryngology (1.1k citations), Pulmonary and Respiratory Medicine (7.4k citations) and Radiology, Nuclear Medicine and Imaging (4.4k citations). Sung‐Bae Kim has collaborated with scholars based in South Korea, United States and Spain. Frequent co-authors include Javier Cortés, Graham A. Ross, Emma Clark, Mark C. Benyunes, Sandra M. Swain, Jean-Marc Ferrero, Jungsil Ro, Seock‐Ah Im, Adam Knott and Eva Ciruelos. Their work appears in journals such as Cancer Research and Treatment, The Lancet Oncology, Breast Cancer Research and Treatment, Journal of Clinical Oncology and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.